Left Ventricular Hypertrophy is outlined as an increase in the mass of the left ventricle, which may also be secondary to an expand in wall thickness, and broaden in cavity measurement. Left ventricular hypertrophy more often than not develops steadily. Whilst ventricular hypertrophy happens naturally as a response to aerobic undertaking and strength coaching, it is most commonly known as a pathological response to cardiovascular disorder, or high blood stress.
Treatment for LVH focuses on the underlying the cause of the condition. Depending on the cause, Treatment may include medication or surgery. Doctor suggests the treatment for LVH such as regular exercise a low-sodium, low-fat diet and no smoking. They used to control the blood pressure by using some types of drugs like enalapril (Vasotec), lisinopril (Prinivil, Zestril) and captopril (Capoten), atenolol (Tenormin), carvedilol (Coreg), metoprolol (Toprol XL) and bisoprolol (Zebeta) and etc.
The prevalence of LVH was 42.7% in 4270 hypertensive patients, with 37.4% in males and 45.4% in females, respectively. The prevalence of concentric remodeling, concentric or eccentric hypertrophy was 24.7%, 20.2%, and 22.6%, respectively. In Logistic regression model, female (OR 1.3, 95%CI 1.1 - 1.5, P < 0.01), age (OR 1.02, 95%CI 1.01 - 1.03, P < 0.01), body mass index (OR 1.2, 95%CI 1.15 - 1.20, P < 0.01), systolic blood pressure (OR 1.02, 95%CI 1.01 - 1.03, P < 0.01), and serum triglyceride (OR 1.10, 95% CI 1.00 - 1.20, P < 0.01) were risk factors of LVH. Female, age, body mass index, systolic blood pressure and serum triglyceride were also risk factors of left ventricular geometric abnormality.